Trial Profile
A Single Arm Phase 2 Study of Talimogene Laherparepvec in Patients With Cutaneous Squamous Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 06 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2026.